Haleon (HLN) Income from Non-Controlling Interests (2021 - 2023)
Haleon (HLN) posted Income from Non-Controlling Interests of $64.5 million for Q4 2023, up 203.39% on a QoQ basis from $21.3 million in Q2 2023, and up 17.07% year-over-year from $55.1 million in Q4 2022.
Haleon (HLN) Income from Non-Controlling Interests (2021 - 2023) Analysis & Trends
Haleon's Income from Non-Controlling Interests history runs 3 years deep, the most recent figure standing at $64.5 million for Q4 2023.
- Quarterly Income from Non-Controlling Interests rose 17.07% year-over-year to $64.5 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $172.7 million (changed N/A YoY) and the FY2025 annual result came in at $17.1 million, down 59.37% from the prior year.
- Income from Non-Controlling Interests was $64.5 million for Q4 2023 at Haleon, up from $21.3 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $64.5 million in Q4 2023 and bottomed at $21.3 million in Q2 2023.
- A 3-year average of $43.3 million and a median of $43.6 million in 2021 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2022 — Income from Non-Controlling Interests increased 2.24% — and 2023, when it advanced 17.07%.
- Haleon's Income from Non-Controlling Interests stood at $53.9 million in 2021, then climbed by 2.24% to $55.1 million in 2022, then rose by 17.07% to $64.5 million in 2023.
- Business Quant data shows HLN's Income from Non-Controlling Interests at $64.5 million in Q4 2023, $21.3 million in Q2 2023, and $31.8 million in Q2 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.06 Bn | 87.19 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.51 Bn | 30.57 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 23.18 Bn | 21.03 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.75 Bn | 16.43 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.63 Bn | 12.21 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.48 Bn | 10.33 Bn | 59.30 Mn | 3.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 64.54 Mn |
| Jun 30, 2023 | 21.27 Mn |
| May 3, 2023 | 31.79 Mn |
| Dec 31, 2022 | 55.13 Mn |
| Sep 20, 2022 | 33.24 Mn |
| Dec 31, 2021 | 53.92 Mn |